Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vopratelimab - Concentra Biosciences

Next Previous
Drug Profile

Vopratelimab - Concentra Biosciences

Alternative Names: ICOS agonist monoclonal antibody; JTX-2011

Latest Information Update: 11 Jun 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jounce Therapeutics
  • Developer Concentra Biosciences
  • Class Antineoplastics; Cell therapies; Immunotherapies; Monoclonal antibodies; T lymphocyte cell therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Inducible T-cell co-stimulator protein agonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer; Solid tumours; Urogenital cancer

Most Recent Events

  • 30 May 2024 Jounce Therapeutics terminates a phase I/II trial in Solid tumours (Monotherapy, Combination therapy, Second-line therapy, Metastatic disease, Late-stage disease) in USA (IV), due to a sponsor decision (NCT04319224)
  • 25 Apr 2024 Jounce Therapeutics terminates enrolment in phase II SELECT trial for Non-small cell lung cancer (Second line therapy or greater, Combination therapy) in Georgia, Latvia, Moldova, Ukraine, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Hungary, Romania, Russia, Serbia, Slovakia, Turkey (NCT04549025)
  • 01 May 2023 Jounce Therapeutics has been acquired and merged into Concentra Biosciences

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top